



Company Overview

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, acute respiratory distress syndrome (ARDS), type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company's lead compound, CB4211, which is under development for the treatment of NASH and obesity, recently completed a successful Phase 1a/1b clinical trial. In addition, CohBar has four preclinical programs, the most advanced of which is CB5138-3, a peptide with broad anti-fibrotic and anti-inflammatory properties. This program is currently in IND-enabling studies with the goal of filing an IND and initiating a First-in-Human study in 2022 with an initial indication of idiopathic pulmonary fibrosis. The company also has a program in ARDS, including COVID-19 associated ARDS, as well as two peptide families with potential utility in treating various forms of cancer.

CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021

Oct 13 2021, 9:00 AM EDT

CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

Oct 5 2021, 9:00 AM EDT

CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

Sep 15 2021, 9:00 AM EDT

Stock Overview

Symbol	CWBR
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week	\$ - \$

Investor Relations

Jordyn Tarazi
Director, Investor Relations
T: (650) 445-4441
jordyn.tarazi@cohbar.com

Management Team

Joseph J. Sarret, M.D., J.D.

Chief Executive Officer and Director

Kenneth C. Cundy, Ph.D.

Chief Scientific Officer

Jeffrey F. Biunno, CPA, MBA

Chief Financial Officer, Secretary and Treasurer

CohBar, Inc.

1455 Adams Drive
Suite 2050
Menlo Park, CA 94025

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

